Omeros Corp - Company Profile
Powered by 
All the data and insights you need on Omeros Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date Omeros Corp Strategy Report
- Understand Omeros Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Omeros Corp Catalyst Calendar
Proactively evaluate Omeros Corp’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Omeros Corp Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 01 Aug 2020 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 01 Feb 2020 | Phase III Trial Completion | Omeros Corp; PSI CRO AG | OMER | narsoplimab | Cardiovascular; Gastrointestinal | Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome); Hemolytic Uremic Syndrome; Thrombotic Microangiopathy | Clinical Trial Registry |
| 31 Dec 2019 | NDA/BLA Filing (US) | Omeros Corp | OMER | narsoplimab | Cardiovascular; Gastrointestinal; Genito Urinary System And Sex Hormones; Immunology | Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome); Hematopoietic Stem Cell Transplantation; IgA Nephropathy (Berger's Disease); Thrombotic Microangiopathy | Company Press Release |
| 01 Oct 2019 | Phase II Trial Completion | Novotech Australia Pty Ltd; Omeros Corp; PSI CRO AG | OMER | narsoplimab | Cardiovascular; Gastrointestinal; Hematological Disorders | Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome); Thrombotic Microangiopathy; Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) | Company Press Release |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer